Helix BioPharma Corp. (HBP : TSX)
Common Stock
$1.94
CAD
-0.05 (-2.51%)
Last updated: 2026-08-26
Get HBP alerts:
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
-2.51%
1 Week
-3.00%
1 Month
+34.72%
YTD
-19.17%
Key Statistics
Market Cap
$151.99M
52W High
$5.40
52W Low
$1.10
P/E Ratio
-
50 Day MA
$1.54
200 Day MA
$1.88
Beta
-0.35
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 8/26/2026 | $1.94 | $1.95 | $1.94 | $1.94 | $1.94 | 5,756 |
| 8/25/2026 | $1.98 | $2.03 | $1.76 | $1.99 | $1.99 | 8,001 |
| 8/24/2026 | $1.98 | $2.02 | $1.83 | $2.01 | $2.01 | 1,444 |
| 8/21/2026 | $2.04 | $2.05 | $1.91 | $1.97 | $1.97 | 2,535 |
| 8/20/2026 | $2.00 | $2.03 | $2.00 | $2.00 | $2.00 | 512 |
| 8/19/2026 | $2.00 | $2.02 | $2.00 | $2.00 | $2.00 | 2,239 |
| 8/18/2026 | $2.06 | $2.08 | $1.99 | $2.00 | $2.00 | 7,148 |
| 8/17/2026 | $1.94 | $2.08 | $1.86 | $2.02 | $2.02 | 6,655 |
| 8/14/2026 | $1.78 | $1.94 | $1.78 | $1.87 | $1.87 | 3,228 |
| 8/13/2026 | $1.70 | $1.80 | $1.68 | $1.80 | $1.80 | 1,454 |
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 28.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+28.9% Upside
Current Price
C$1.94
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
40.0%
Annualized
90-Day Vol
58.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.06 | C$1.79 – C$2.36 |
| 60 trading days | C$2.19 | C$1.80 – C$2.66 |
| 90 trading days | C$2.32 | C$1.83 – C$2.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BNG | Bengal Energy Ltd | $0.03 | +25.00% |
| KRN | Karnalyte Resources Inc. | $0.32 | +10.34% |
| FRX | Fennec Pharmaceuticals Inc | $17.00 | +9.75% |
| BCT | Briacell Therapeutics Corp | $5.62 | +9.34% |
| YRB | Yorbeau Resources Inc | $0.06 | +9.09% |
| PRU | Perseus Mining Ltd | $6.58 | +7.69% |
| CRDL | Cardiol Therapeutics Inc Class A | $2.97 | +7.61% |
| SLT | Saltire Capital Ltd. | $2.70 | +7.57% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWhat's Going On With Helix BioPharma Corp. Stock Thursday?
August 2026
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- Why Helix BioPharma Corp. stock is gaining today
- Why Helix BioPharma Corp. stock is rising today
- Why Helix BioPharma Corp. stock is skyrocketing today
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- Why Helix BioPharma Corp. stock is rising today
- Why Helix BioPharma Corp. stock is rising today
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- Why Helix BioPharma Corp. stock is sliding today